Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.
Press Enter β΅ to search evidence
Explore by Goal
"The most incomprehensible thing about the world is that it is comprehensible."
- Albert Einstein
Quick Explanation
Copied
The FSCN1βTHBS1 study (GSE197621/GSE197624) presents a coherent RBP-axis mechanism with public data and rescue controls, but the available records contain no reported RIP-seq peak statistics or RNA-binding motif/consensus analysis for THBS1, so any independent peak/motif reanalysis must be done de novo from the deposited FASTQ/peak files .
Long Explanation
Evidence Basis and What a Reanalysis Can Test
The paper reports that FSCN1, classically an actin-bundling protein, acts as an RNA-binding protein that stabilizes THBS1 mRNA by binding its coding sequence, activating TGF-Ξ² signaling (Cyr61/CTGF readouts) and driving ESCC metastasis . The key mechanistic anchor is a ~153 bp CDS binding window with deletion mutants (Ξ1/Ξ2) validated by RIP-qPCR and luciferase reporter assays.
What the records do NOT contain: no RIP-seq peak counts, IDR/replicate concordance statistics, CLIP-type crosslink resolution, or any computed RNA sequence motif/consensus enriched under FSCN1 peaks. The title of the query ('peak motif reanalysis') therefore targets an analysis that the source paper apparently did not perform or report β the binding site was defined functionally by deletion mapping, not by motif discovery. An independent reanalysis would need to download GSE197621 (RNA-seq) and GSE197624 (RIP-seq), call peaks (e.g., Piranha/CLIPper), test reproducibility, and scan the 153 bp Ξ1 window for sequence/structural motifs (e.g., U/G-rich or stem-loop features) using MEME/RBPmap.
These magnitudes are internally consistent (FSCN1 KD β THBS1 mRNA β~70% with protein concordance) and supported by a strong clinical FSCN1βTHBS1 co-expression correlation (rΒ² = 0.6410, i.e., r β 0.80) across 55 ESCC TMAs .
Critical Gaps and Blind Spots
No motif identified: a 'peak motif reanalysis' must start from raw reads; the paper only localizes binding to one CDS region. Without a consensus motif, the Ξ1/Ξ2 functional mapping cannot be tied to direct sequence recognition vs indirect proteinβRNA bridging.
Partial CDS coverage: authors acknowledge binding was demonstrated only on partial THBS1 CDS segments, not full structural mapping β so peak calling across the full transcript is warranted and could reveal additional binding sites .
Single-country cohort: the 55-sample TMA cohort is China-based; THBS1 protein overexpression in ESCC was previously reported at 72/80 cases (90%) in an independent Shantou cohort with stage/nodal association (P=0.029/0.026), supporting biological plausibility but not independent FSCN1 correlation .
FSCN1 pan-cancer context: FSCN1 overexpression and poor-prognosis association is not ESCC-specific β it was reported in NSCLC (6.47-fold mRNA increase, P<0.001; 53.2% high protein expression) and downstream of SNAI2 in HNSC (r=0.63 with SNAI2 in TCGA-HNSC, N=520) β meaning a motif found under FSCN1 RIP peaks would likely generalize across squamous tumors, a testable prediction, not an established fact.
Directionality tension: in the ESCC axis THBS1 is pro-metastatic (FSCN1-driven), whereas THBS1 is context-dependent elsewhere (e.g., anti-inflammatory in melatonin-treated bladder epithelium, pro-inflammatory via RhoA/ROCK1 in trophoblasts) β reanalysis conclusions should not assume a universal THBS1 effect.
Bottom line: the study's core causal chain (FSCN1 β THBS1 stability β TGF-Ξ² β metastasis) is well-controlled (rescue experiments both directions, ActD decay, in vivo xenograft/metastasis models), but the RIP-seq peak/motif layer is under-reported in available records. A rigorous reanalysis of GSE197621/GSE197624 β peak calling, replicate reproducibility, motif discovery at the Ξ1 window, and cross-cancer motif comparison β would be the highest-value independent contribution and could confirm or refute direct sequence-specific binding.
Feedback:
Updated: November 17, 2026
BGPT Paper Review
Study Novelty
90%
First demonstration of FSCN1 as an RNA-binding protein stabilizing a specific mRNA (THBS1) via CDS binding, with acetylation as a regulatory switch β a genuinely new function for a well-known actin-bundling protein.
Scientific Quality
80%
Strong internal controls (bidirectional rescue, ActD decay, luciferase deletion mutants, in vivo xenograft/metastasis). Deductions: RIP-seq peak statistics and motif analysis not reported in available records; binding mapped only to partial CDS segments; no PDX models; cohort limited to one country and 55 samples.
Study Generality
70%
The FSCN1βRBP mechanism may generalize across squamous carcinomas where FSCN1 is overexpressed, but the specific THBS1βTGF-Ξ² axis is tested only in ESCC; generality awaits cross-cancer validation.
Study Usefulness
80%
Identifies a post-translational (acetylation) vulnerability in an RBP-metastasis axis with public GEO data enabling independent reanalysis and target validation.
Study Reproducibility
80%
RNA-seq and RIP-seq deposited (GSE197621, GSE197624), source data and uncropped blots in supplementary files; cell lines and mouse models specified; exact FSCN1-mut acetylation-site residues not detailed in available records.
Explanatory Depth
80%
Mechanistic chain from RNA binding β mRNA stability β protein β TGF-Ξ² readouts β metastasis is complete with rescue logic; deeper structural mapping of the RNAβprotein interface is missing.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
FSCN1 promotes metastasis purely through actin bundling and cell motility β no longer sufficient, since FSCN1-KD reduces THBS1 mRNA stability and THBS1-OE rescues the phenotype without altering actin bundling activity.